Penpulimab
- Generic Name
- Penpulimab
- Drug Type
- Biotech
- CAS Number
- 2350298-92-7
- Unique Ingredient Identifier
- IBS1BZ4E4I
- Indication
适用于至少经过二线系统化疗的复发或难治性经典型霍奇金淋巴瘤成人患者。
A Study of Anlotinib and AK105 Injection in Subjects With Gastrointestinal Tumors, Urinary System Tumors, Neuroendocrine Tumors
- Conditions
- Gastrointestinal Tumors, Urinary System Tumors, Neuroendocrine Tumors
- Interventions
- First Posted Date
- 2019-12-20
- Last Posted Date
- 2020-06-17
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 150
- Registration Number
- NCT04207463
- Locations
- 🇨🇳
Jinan Central Hospital, Jinan, Shandong, China
🇨🇳Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China
🇨🇳Harbin Medical University Cancer Hospital, Harbin, Jilin, China
A Study of Anlotinib and AK105 Injection in Subjects With Advanced Head, Neck and Chest Cancer
- First Posted Date
- 2019-12-18
- Last Posted Date
- 2020-06-23
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 140
- Registration Number
- NCT04203719
- Locations
- 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China
A Study to Evaluate the Efficacy and Safety of Anti-PD-1 Antibody AK105 in Patients With Selected Advanced Solid Tumors
- First Posted Date
- 2019-11-21
- Last Posted Date
- 2025-03-12
- Lead Sponsor
- Akeso
- Target Recruit Count
- 65
- Registration Number
- NCT04172506
- Locations
- 🇨🇳
The First Affiliated Hospital of Zhejiang University, Hangzhou, Zhejiang, China
A Study of Anti-PD-1 AK105 in Patients With Metastatic Nasopharyngeal Carcinoma
- First Posted Date
- 2019-03-07
- Last Posted Date
- 2025-02-27
- Lead Sponsor
- Akeso
- Target Recruit Count
- 130
- Registration Number
- NCT03866967
- Locations
- 🇨🇳
FuDan University Shanghai Cancer Center, Shanghai, Shanghai, China
🇨🇳Beijing Cancer Hospital, Beijing, Beijing, China
Study of the Safety, Pharmacokinetics, and Antitumor Activity of AK105 in Subjects With Advanced Solid Tumors
- First Posted Date
- 2017-11-24
- Last Posted Date
- 2025-02-28
- Lead Sponsor
- Akesobio Australia Pty Ltd
- Target Recruit Count
- 99
- Registration Number
- NCT03352531
- Locations
- 🇦🇺
St Vincent's Hospital, Sydney (The Kinghorn Cancer Centre), Darlinghurst, New South Wales, Australia
🇦🇺Border Medical Oncology, East Albury, New South Wales, Australia
🇦🇺ICON Cancer Foundation, South Brisbane, Queensland, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.